PF413 CARDIAC, VASCULAR, AND HYPERTENSION SAFETY OF BOSUTINIB VS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL

Authors :: C. Gambacorti-Passerini
Eric Leip
Andrea Viqueira
M. Deininger
Vamsi Kota
R. Clark
J. E. Cortes
Tim H. Brümmendorf
Source :: HemaSphere. 3:159
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Internal medicine
Medicine
Myeloid leukemia
Imatinib
Hematology
Newly diagnosed
business
Bosutinib
medicine.drug

Tools